Key Highlights
- $54 million Series A financing led by 8VC and DCVC Bio.
- Focus on gene therapy candidates for CLN2 disease and Huntington’s disease.
- Proprietary AAV capsid variants showcased high gene expression in preclinical models.
Source: Business Wire
Notable Quotes
- “We are excited to introduce Latus and our novel approaches to developing AAV-mediated gene therapies, which we believe have the potential to transform the treatment landscape for genetically-defined CNS disorders,” – P. Peter Ghoroghchian, CEO at Latus
- “Empowering this science, team, and mission is the kind of work that makes you so grateful to be an investor,” – Francisco Gimenez, Partner at 8VC
- “The team at Latus has aggregated an immense pool of technology and know-how that we believe could lead them to overcome limitations that have been plaguing the modality,” – Kiersten Stead, Managing Partner at DCVC Bio
SoHC's Take
Latus Bio, Inc. is spearheading a significant shift in the treatment of central nervous system disorders with its innovative gene therapy platform. Their proprietary AAV capsid technologies promise to enhance the specificity and efficacy of gene therapy applications, thereby potentially reducing the treatment burden and improving patient outcomes. With a robust development pipeline and the backing of major investors and research institutions, Latus Bio is well-positioned to lead advancements in this challenging field.
